Aljohani Abrar I
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.
Medicina (Kaunas). 2024 Nov 23;60(12):1929. doi: 10.3390/medicina60121929.
: Invasive breast cancer (BC) was traditionally investigated visually, and no technique could identify the key molecular drivers of patient survival. However, essential molecular drivers of invasive BC have now been discovered using innovative genomic, transcriptomic, and proteomic methodologies. Nevertheless, few evaluations of the prognostic factors of BC in Saudi Arabia have been performed. Evaluating the biomarkers associated with the development of early-stage BC could help determine the risk of metastasis and guide treatment decisions. In a previous study, using large BC cohorts and artificial neural network techniques, DNA replication and sister chromatid cohesion 1 () was found to be one of the principal genes in invasive BC samples. To date, no studies have addressed the prognostic significance of in invasive BC and its association with aggressive tumor behavior. This research aimed to address this gap. : The association of clinicopathological features and patient outcomes with expression at the mRNA level was assessed using the Molecular Taxonomy Breast Cancer International Consortium (METABRIC; = 1980) and The Cancer Genome Atlas (TCGA; = 854) cohorts. was also evaluated at the protein level using immunohistochemistry on samples from invasive BC patients ( = 100) presenting to King Abdul Aziz Specialist Hospital in Saudi Arabia. The association of clinicopathological parameters (including patient age, tumor grade, tumor size, and patient outcome) with protein level was also evaluated. : In both METABRIC and TCGA cohorts, high expression of was significantly associated with high histological grade, large tumor size, lymphovascular invasion positivity, and hormone receptor negativity (all < 0.001). A high mRNA level was associated with poor outcomes ( < 0.001 for METABRIC, = 0.23 for TCGA). At the protein level, high DSCC1 expression was associated with high histological grade ( = 0.001), lymph node presence ( = 0.008), hormone receptor negativity ( = 0.005), high Ki67 expression ( = 0.036), and shorter survival ( = 0.008). : This study confirmed the prognostic significance of DSCC1 in invasive BC patients. DSCC1 could be a therapeutic target in BC cases with poor outcomes.
浸润性乳腺癌（BC）传统上是通过肉眼检查来研究的，没有技术能够识别患者生存的关键分子驱动因素。然而，现在已经使用创新的基因组学、转录组学和蛋白质组学方法发现了浸润性BC的关键分子驱动因素。尽管如此，沙特阿拉伯对BC预后因素的评估却很少。评估与早期BC发展相关的生物标志物有助于确定转移风险并指导治疗决策。在先前的一项研究中，使用大型BC队列和人工神经网络技术，发现DNA复制和姐妹染色单体黏连蛋白1（DSCC1）是浸润性BC样本中的主要基因之一。迄今为止，尚无研究探讨DSCC1在浸润性BC中的预后意义及其与侵袭性肿瘤行为的关联。本研究旨在填补这一空白。：使用国际乳腺癌分子分类联盟（METABRIC；n = 1980）和癌症基因组图谱（TCGA；n = 854）队列评估临床病理特征和患者预后与DSCC1 mRNA水平表达的关联。还使用免疫组织化学对来自沙特阿拉伯阿卜杜勒阿齐兹国王专科医院的浸润性BC患者样本（n = 100）进行蛋白质水平的DSCC1评估。还评估了临床病理参数（包括患者年龄、肿瘤分级、肿瘤大小和患者预后）与蛋白质水平的关联。：在METABRIC和TCGA队列中，DSCC1的高表达均与高组织学分级、大肿瘤大小、淋巴管浸润阳性和激素受体阴性显著相关（均P < 0.001）。高DSCC1 mRNA水平与不良预后相关（METABRIC中P < 0.001，TCGA中P = 0.23）。在蛋白质水平上，高DSCC1表达与高组织学分级（P = 0.001）、淋巴结转移（P = 0.008）、激素受体阴性（P = 0.005）、高Ki67表达（P = 0.036）和较短生存期（P = 0.008）相关。：本研究证实了DSCC1在浸润性BC患者中的预后意义。DSCC1可能是预后不良的BC病例的治疗靶点。
